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1. INTRODUCTION {#all13593-sec-0005}
===============

Previous studies have shown that early wheezing induced by rhinovirus and/or associated with sensitization is an important risk factor for recurrent wheezing and asthma. They are likely to reveal the underlying airway inflammation and the weaknesses in viral defense mechanisms.[1](#all13593-bib-0001){ref-type="ref"}, [2](#all13593-bib-0002){ref-type="ref"}, [3](#all13593-bib-0003){ref-type="ref"} However, the factors influencing bronchial reactivity in children are poorly characterized. Previous studies have shown that early‐life factors, such as early‐onset atopy,[4](#all13593-bib-0004){ref-type="ref"}, [5](#all13593-bib-0005){ref-type="ref"}, [6](#all13593-bib-0006){ref-type="ref"}, [7](#all13593-bib-0007){ref-type="ref"} family history of asthma,[6](#all13593-bib-0006){ref-type="ref"}, [8](#all13593-bib-0008){ref-type="ref"} maternal smoking,[4](#all13593-bib-0004){ref-type="ref"}, [5](#all13593-bib-0005){ref-type="ref"}, [6](#all13593-bib-0006){ref-type="ref"}, [8](#all13593-bib-0008){ref-type="ref"}, [9](#all13593-bib-0009){ref-type="ref"} exposure to traffic‐related air pollution,[10](#all13593-bib-0010){ref-type="ref"}, [11](#all13593-bib-0011){ref-type="ref"} preterm birth,[12](#all13593-bib-0012){ref-type="ref"}, [13](#all13593-bib-0013){ref-type="ref"}, [14](#all13593-bib-0014){ref-type="ref"} and low birth weight,[15](#all13593-bib-0015){ref-type="ref"} may be associated with decreased pulmonary function in later childhood. Two studies have shown that wheezing at young age, induced by rhinovirus, may be associated with decreased pulmonary function or increased airway reactivity later in childhood.[8](#all13593-bib-0008){ref-type="ref"}, [16](#all13593-bib-0016){ref-type="ref"} Some[5](#all13593-bib-0005){ref-type="ref"}, [17](#all13593-bib-0017){ref-type="ref"}, [18](#all13593-bib-0018){ref-type="ref"} but not all[9](#all13593-bib-0009){ref-type="ref"}, [19](#all13593-bib-0019){ref-type="ref"} studies have shown a comparable association between respiratory syncytial virus (RSV)‐induced wheezing and reduced pulmonary function. However, these earlier studies mainly included older children, and there were no data from the first virus‐induced wheezing episode.

Pulmonary function testing in young children is challenging. Impulse oscillometry (IOS) is a method for testing pulmonary function during tidal breathing.[20](#all13593-bib-0020){ref-type="ref"}, [21](#all13593-bib-0021){ref-type="ref"}, [22](#all13593-bib-0022){ref-type="ref"}, [23](#all13593-bib-0023){ref-type="ref"} A key measurement in IOS is respiratory resistance (Rrs) which indicates the energy loss due to resistive forces to the airflow in the airways and is clinically interpreted as an indicator of obstruction. IOS is child‐friendly as it requires a minimum cooperation and has successfully been used from the age of 2‐3 years forward.[21](#all13593-bib-0021){ref-type="ref"}, [24](#all13593-bib-0024){ref-type="ref"} In Finland, there are population‐based reference values available for children aged 2‐7 years.[20](#all13593-bib-0020){ref-type="ref"}, [23](#all13593-bib-0023){ref-type="ref"}

Secondary strategies to prevent asthma can be initiated at the time of the first wheezing episode.[25](#all13593-bib-0025){ref-type="ref"}, [26](#all13593-bib-0026){ref-type="ref"}, [27](#all13593-bib-0027){ref-type="ref"}, [28](#all13593-bib-0028){ref-type="ref"} However, it is not known which patient characteristics at the time of the first acute wheezing episode predict abnormal pulmonary function during the later childhood. Thus, among children who had suffered from the first acute severe wheezing episode before the age of 2 years, we aimed to determine the pulmonary function at the age of 5 years and its reactivity to exercise or bronchodilation by IOS. We also tested for early‐life factors predicting the exercise or bronchodilation‐induced bronchial reactivity. We hypothesized that patient characteristics, such as rhinovirus etiology and atopy at the time of the first severe wheezing episode, would be associated with the pulmonary function and increased bronchial reactivity measured by IOS 4 years after the first wheezing episode.

2. METHODS {#all13593-sec-0006}
==========

2.1. Subjects {#all13593-sec-0007}
-------------

This study is a part of a larger Vinku2 study which was carried out in the Turku University Hospital (recruitment June 2007 to March 2009).[3](#all13593-bib-0003){ref-type="ref"}, [27](#all13593-bib-0027){ref-type="ref"}, [29](#all13593-bib-0029){ref-type="ref"} The aim of the original study was to assess the effect of a 3‐day course of oral prednisolone (first dose 2 mg/kg, then 2 mg/kg/day in two divided doses, maximum dose 60 mg/day, Prednisolon^®^ 5 mg tablets, Leiras Takeda, Helsinki, Finland) in children with the first acute rhinovirus‐induced wheezing episode (79% hospitalized; 21% treated at emergency room of tertiary hospital) using a randomized double‐blind placebo‐controlled paralleled design. The inclusion criteria were age 3‐23 months, first acute wheezing episode (confirmed by parental report and medical records), and delivery at ≥36 weeks. Children with chronic nonatopic illnesses, need for intensive care unit treatment, or previous systemic or inhaled corticosteroid (ICS) treatment were excluded from the study. The study was approved by the Ethics Committee of the Turku University Hospital and was commenced after obtaining written informed consent from guardians. The trial was double‐blinded until the 12‐month follow‐up.

2.2. Study protocol {#all13593-sec-0008}
-------------------

At study entry, the guardian completed a standard questionnaire form, the child was physically examined, a nasopharyngeal aspirate sample was taken using a standardized procedure,[30](#all13593-bib-0030){ref-type="ref"} and blood sample was drawn. The study drug was initiated if nasopharyngeal aspirate was rhinovirus PCR positive. Pulmonary function was evaluated at the follow‐up visit four years later (1‐5/2012, 8‐10/2012) by IOS (Jaeger GmbH, Würzburg, Germany, see below for more details). The guardians were instructed to discontinue the ICS treatment of the children 4 weeks before the 4‐year follow‐up visit. The study protocol was registered at ClinicalTrials.gov in August 2008 (ClinicalTrials.gov number NCT00731575).

2.3. Laboratory methods {#all13593-sec-0009}
-----------------------

At study entry, multiplex (Seeplex RV12 ACE Detection, Seegene, Seoul, Korea) or *in‐house* single PCR tests were used for detecting adenovirus, coronavirus 229E, NL63 and HKU1, enteroviruses, human bocavirus, human metapneumovirus, influenza A and B viruses, parainfluenza virus types 1‐3, rhinovirus types A, B, and C, and RSV A and B at the Department of Virology, University of Turku.[29](#all13593-bib-0029){ref-type="ref"} Rhinovirus sequencing has previously been described and analyzed in collaboration with the University of Wisconsin‐Madison.[31](#all13593-bib-0031){ref-type="ref"}, [32](#all13593-bib-0032){ref-type="ref"} Human bocavirus‐1 was also analyzed using serology, as previously described.[33](#all13593-bib-0033){ref-type="ref"} To analyze the virus genome load, a sterile flocked swab (catalog number 502CS01, Copan, Brescia, Italy) was first dipped in the aspirate and then diluted with 1 mL of phosphate‐buffered saline. The genome load was analyzed from RNA of rhinovirus‐positive samples by a quantitative RT‐PCR, using known concentrations of rhinovirus‐B14 plasmid. The plasmid was received from Glyn Stanway at the University of Colchester (Essex, UK) and has been described elsewhere.[34](#all13593-bib-0034){ref-type="ref"} Serum levels of allergen‐specific immunoglobulin E (IgE, Phadiatop Combi^®^, Phadia, Uppsala, Sweden) and blood eosinophil counts (B‐eos) were analyzed by the Central Laboratory of the Turku University Hospital. Serum 25‐hydroxyvitamin D (25‐OH‐D) measurements were taken using liquid chromatography tandem mass spectrometry at the Massachusetts General Hospital (Boston, USA).

2.4. Impulse oscillometry {#all13593-sec-0010}
-------------------------

The airway hyperresponsiveness and reversible airflow obstruction were measured using IOS.[20](#all13593-bib-0020){ref-type="ref"}, [21](#all13593-bib-0021){ref-type="ref"}, [22](#all13593-bib-0022){ref-type="ref"}, [23](#all13593-bib-0023){ref-type="ref"} The impulse oscillatory signals of 5‐35 Hz were used and output pressure and flow signals analyzed for their amplitude and phase difference, to determine the airway resistance (Rrs, variable that reflects the energy loss due to resistive forces to the airflow) and the reactance (Xrs, indicator of viscoelastic properties of the small airways). Rrs and Xrs both are components of total respiratory impedance (Zrs, results from phase and pressure changes of the airflow). The frequency dependency of resistance (dRrs/df) was determined using linear regression through resistance data points Rrs5 and Rrs10. During obstruction, Rrs increases resulting in increased dRrs/df. Xrs decreases due to peripheral stiffening as a result of obstruction. The technical realization of IOS is described in more detail in Appendix [S1](#all13593-sup-0001){ref-type="supplementary-material"}.

After the baseline measurements, a 6‐minute exercise test was conducted. The children were urged to run 6‐8 min at an exercise level where the heart rate was held at 85%‐90% of their estimated maximum heart rate (205−1/2 ×  age), assessed with a heart rate monitor (Polar Sport Tester^®^, Polar Elektro Ltd, Kempele, Finland). IOS measurement was repeated 1, 5, and 10 min after the exercise testing.[23](#all13593-bib-0023){ref-type="ref"}, [35](#all13593-bib-0035){ref-type="ref"}, [36](#all13593-bib-0036){ref-type="ref"} Finally, the reversible airflow obstruction was assessed with IOS 15 min after the bronchodilation with inhalation of 400 micrograms of salbutamol (Ventolin^®^) administered through a spacer (Babyhaler^®^); both products are from GlaxoSmithKline (Brentford, UK).[20](#all13593-bib-0020){ref-type="ref"} The results were proportioned by the height of the child. Rrs at 5 Hz was categorized as pathological if exercise‐induced change in mean crude values was +35% or more[2](#all13593-bib-0002){ref-type="ref"} or if bronchodilator‐induced change in mean crude values was −35% or more[23](#all13593-bib-0023){ref-type="ref"}, [36](#all13593-bib-0036){ref-type="ref"} (Malmberg 2008, Beydon 2007).

2.5. Definitions {#all13593-sec-0011}
----------------

Children had atopic sensitization if they had a positive test (cutoff level ≥0.35 kU/L) for IgE specific for any of tested allergens (codfish, cow\'s milk, egg, peanut, soybean, wheat, cat, dog, horse, birch, mugwort, timothy, *Cladosporium herbarum*, and *Dermatophagoides pteronyssinus*).[29](#all13593-bib-0029){ref-type="ref"} Eczema at study entry was a physician‐made diagnosis according to pruritus, typical morphology, and chronicity of disease and it was defined as atopic if any sensitization was diagnosed.

2.6. Statistical methods {#all13593-sec-0012}
------------------------

Baseline differences between groups of different characteristics were analyzed with two‐sample *t*‐test (normally distributed variables), Mann‐Whitney *U* test (skewed variables), chi‐square test, or Fisher\'s exact test (categorical data). Results are expressed as mean (standard deviation, SD) when normally distributed, median (interquartile range, IQR) when they had skewed distribution, and numbers (%) for categorical variables. The normality of the variables was assessed with Kolmogorov‐Smirnov test. Natural logarithmic (ln) change was applied for Rrs 5 Hz before the multivariable regression analysis due to the positively skewed distribution. Logistic and linear regression analyses were used for multivariable analyses. Results of logistic regression analyses are expressed as odds ratios (OR) with 95% confidence interval (95%CI) and results of linear regression analyses as regression coefficient beta (β) with 95%CI. Multivariable models included age, oral corticosteroid (OCS) treatment, and rhinovirus at study entry and depending on the dependent variable also atopic sensitization, seasonal sensitization, atopic eczema, hospitalization at study entry, and/or ICS within 4 weeks. Data were analyzed using IBM SPSS version 24 (SPSS Inc, Chicago, IL, USA). A statistical power analysis was not conducted for IOS outcomes (Jartti 2015). A two‐sided *P *\<* *0.05 was considered statistically significant.

3. RESULTS {#all13593-sec-0013}
==========

3.1. Study cohort {#all13593-sec-0014}
-----------------

Seventy‐seven (62%) of the 124 enrolled children attended the 4‐year follow‐up visit (Figure [1](#all13593-fig-0001){ref-type="fig"}). IOS and bronchodilation tests were conducted for 76/77 (99%) children and exercise test for 73/77 (95%) children. Exercise test was not conducted due to refusal of running in two (3%) children and due to severe asthma symptoms in one (1%) child. All the children with bronchodilation and/or exercise test (n = 76) were included in the analysis. The included (n = 76) and excluded (n = 48) participants did not differ from one another concerning the patient characteristics shown in Table [1](#all13593-tbl-0001){ref-type="table"} (Table [S1](#all13593-sup-0001){ref-type="supplementary-material"}).

![Study flowchart](ALL-74-518-g001){#all13593-fig-0001}

###### 

Patient characteristics at study entry

  Characteristic                                             N = 76
  ---------------------------------------------------------- ------------------
  Age, months                                                12 (6.0)
  Male sex, no.                                              50 (66%)
  Hospitalized at study entry, no.                           62 (82%)
  OCS treatment, no.                                         21 (28%)
  Atopic eczema, no.                                         13 (17%)
  B‐eos, ×10^9^/L                                            0.27 (0.16‐0.58)
  B‐eos \> 0.4 × 10^9^/L, no.                                32/74 (43%)
  Atopic sensitization, no.                                  22/74 (30%)
  Food sensitization, no.                                    21/74 (28%)
  Aeroallergen sensitization, no.                            11/74 (15%)
  Seasonal sensitization, no.                                5/74 (7%)
  Perennial sensitization, no.                               10/74 (14%)
  Parental asthma, no.                                       16 (21%)
  Parental smoking, no.                                      30 (40%)
  Maternal smoking, no.                                      15 (20%)
  Virus positive, no.                                        76 (100%)
  Rhinovirus, no.                                            57 (75%)
  Rhinovirus repeated during the first‐year follow‐up, no.   47/56 (83%)
  Rhinovirus genome load, copies/mL                          4000 (49‐17 000)
  Rhinovirus genome load \>7000 copies/mL, no.               20/50 (40%)
  Rhinovirus genome load \>9000 copies/mL, no.               18/50 (36%)
  RSV, no.                                                   20 (26%)
  Other virus, no.                                           30 (40%)
  Co‐infection, no.                                          26 (34%)
  25‐hydroxyvitamin D, nmol/L                                88 (20)
  25‐hydroxyvitamin D \> 75 nmol/L, no.                      52/73 (71%)
  Regular ICS medication at 4‐year follow‐up                 37 (75%)
  ICS discontinued ≥4 weeks before testing                   25/37 (68%)

Data are expressed as mean (SD) when normally distributed and median (interquartile range) when not normally distributed or number (%) unless otherwise noted. B‐eos, blood eosinophil count; OCS, oral corticosteroid; RSV, respiratory syncytial virus.
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3.2. Patient characteristics {#all13593-sec-0015}
----------------------------

At study entry, the mean age of the 76 study subjects was 12 months (SD 6.0), 62 of them (82%) were hospitalized, and 50 (66%) children were boys. At least one virus was found in the airways of all of the children. The most common virus was rhinovirus, which was found in 57 (75%) children. RSV was found in 20 (26%) children and other viruses in 30 (40%) children. At least two viruses were found in the airways of 26 (34%) children. During the first wheezing episode, 22/74 (30%) had atopic sensitization, 11/74 (15%) had aeroallergen sensitization, and 21/74 (28%) had food sensitization (Table [1](#all13593-tbl-0001){ref-type="table"}).

At the 4‐year follow‐up visit, the mean age of the children was 60 months (SD 7.9 months). Thirty‐seven (49%) children used ICS treatment during the 12 months preceding the 4‐year follow‐up visit. Asthma medication was discontinued ≥4 weeks prior to the exercise testing in 25 children (68% of the children using ICS) (Table [1](#all13593-tbl-0001){ref-type="table"}).

3.3. Baseline pulmonary function at 4‐year visit {#all13593-sec-0016}
------------------------------------------------

In baseline IOS measurements, one (1%) child had a pathological Rrs 5 Hz (*z*‐score \>+1.65) value and one (1%) child a pathological Xrs 5 Hz (*z*‐score \<−1.65) value when compared to Finnish height‐adjusted reference values. Absolute IOS values are shown in Table [S2](#all13593-sup-0001){ref-type="supplementary-material"}. Children who had atopic eczema (β −0.74; 95%CI −1.4 to −0.11; *P *=* *0.022) or seasonal atopic sensitization (β −1.1; 95%CI −2.1 to −0.14; *P *=* *0.025) at study entry had lower Xrs 5 Hz *z*‐score at baseline measurement than the children with no atopic eczema or seasonal sensitization, respectively. These results, however, were not statistically significant in multivariable analyses which included age, OCS for the first wheezing episode, rhinovirus etiology, and ICS use 4 weeks before the oscillometry. In multivariable analysis, age at study entry for acute wheezing was associated with decreased Xrs 5 Hz (β −0.052; 95%CI −0.095 to −0.009; *P *=* *0.019); that is, the older the age at study entry, the lower the compliance of the lung tissue due to small airway obstruction. Other factors, such as virus etiology, shown in Table [2](#all13593-tbl-0002){ref-type="table"} were not associated with the baseline values of IOS (Table [S3](#all13593-sup-0001){ref-type="supplementary-material"}). Baseline Rrs 10 values were not associated with any of the factors shown in Table [2](#all13593-tbl-0002){ref-type="table"} (data not shown).

###### 

Patient characteristics vs pulmonary function

  Characteristic                                             Baseline Rrs 5 Hz (*z*‐score)         Postexercise Rrs 5 Hz change ≥35% (n = 8)                                    
  ---------------------------------------------------------- ------------------------------------- ------------------------------------------- -------------------------------- -------------------------------
  Age at study entry, months                                 −0.008 (−0.046, 0.030) *P *=* *0.69   −0.11 (−0.54, 0.32) *P *=* *0.62            1.1 (0.97, 1.3) *P *=* *0.15     0.98 (0.84, 1.1) *P *=* *0.83
  Age at 4‐year follow‐up, months                            −0.13 (−0.47, 0.22) *P *=* *0.47                                                  1.7 (0.55, 5.5) *P *=* *0.35     
  Male sex                                                   −0.088 (−0.57, 0.39) *P *=* *0.71                                                 3.7 (0.43, 32) *P *=* *0.23      
  Hospitalized at study entry                                0.080 (−0.50, 0.66) *P *=* *0.79                                                  n/a *P *=* *1.0                  
  OCS at study entry                                         −0.085 (−0.59, 0.42) *P *=* *0.74     −3.1 (−8.7, 2.5) *P *=* *0.28               2.9 (0.65, 13) *P *=* *0.16      1.7 (0.34, 8.9) *P *=* *0.51
  Atopic eczema at study entry                               0.33 (−0.28, 0.92) *P *=* *0.28                                                   ***14 (2.7, 72) P = 0.002***     
  B‐eos \> 0.4 × 10^9^/L, at study entry                     −0.36 (−0.82, 0.096) *P *=* *0.12                                                 3.6 (0.65, 20) *P *=* *0.14      
  Atopic sensitization at study entry                        0.18 (−0.32, 0.69) *P *=* *0.48       −0.27 (−5.9, 5.4) *P *=* *0.92              ***10 (1.8, 55) P = 0.008***     ***8.8 (1.2, 64) P = 0.03***
  Food sensitization at study entry                          0.16 (−0.35, 0.67) *P *=* *0.54                                                   ***11 (2.0, 60) P = 0.006***     
  Aeroallergen sensitization at study entry                  0.23 (−0.42, 0.88) *P *=* *0.48                                                   ***9.8 (1.9, 50) P = 0.006***    
  Seasonal sensitization at study entry                      1.0 (−1.5, 3.6) *P *=* *0.32                                                      ***11 (1.2, 88) P = 0.03***      
  Perennial sensitization at study entry                     0.29 (−0.38, 0.96) *P *=* *0.40                                                   ***5.9 (1.1, 31) P = 0.04***     
  Parental asthma                                            0.080 (−0.47, 0.64) *P *=* *0.77                                                  0.49 (0.055, 4.3) *P *=* *0.52   
  Parental smoking at study entry                            0.22 (−0.24, 0.68) *P *=* *0.34                                                   0.92 (0.20, 4.2) *P *=* *0.92    
  Maternal smoking at study entry                            −0.10 (−0.67, 0.47) *P *=* *0.72                                                  0.53 (0.060, 4.7) *P *=* *0.57   
  Rhinovirus at study entry                                  −0.17 (−0.69, 0.35) *P *=* *0.52      −0.97 (−7.1, 5.2) *P *=* *0.75              n/a *P *=* *1.0                  n/a *P *=* *1.0
  Rhinovirus repeated during the first‐year follow‐up, no.   −0.10 (−0.86, 0.65) *P *=* *0.78                                                  1.2 (0.13, 12) *P *=* *0.86      
  Rhinovirus genome load \>7000 copies/mL                    −0.30 (−0.92, 0.32) *P *=* *0.33                                                  0.17 (0.019, 1.5) *P *=* *0.11   
  Rhinovirus genome load \>9000 copies/mL                    −0.34 (−0.97, 0.29) *P *=* *0.29                                                  0.20 (0.023, 1.8) *P *=* *0.15   
  RSV                                                        0.049 (−0.47, 0.56) *P *=* *0.85                                                  n/a *P *=* *1.0                  
  Other virus                                                −0.057 (−0.52, 0.41) *P *=* *0.81                                                 0.48 (0.090, 2.6) *P *=* *0.39   
  Co‐infection                                               −0.085 (−0.56, 0.39) *P *=* *0.72                                                 0.58 (0.11, 3.1) *P *=* *0.53    
  25‐hydroxyvitamin D, nmol/L                                0.004 (−0.008, 0.015) *P *=* *0.51                                                1.0 (0.96, 1.03) *P *=* *0.88    
  25‐hydroxyvitamin D, \>75 nmol/L, no.                      0.22 (−0.30, 0.73) *P *=* *0.41                                                   3.2 (0.37, 28) *P *=* *0.29      
  ICS within 4 weeks                                         0.096 (−0.52, 0.72) *P *=* *0.76                                                  4.4 (0.87, 22) *P *=* *0.074     

For baseline values, 2‐sample *t*‐test and linear regression analysis were used and results are expressed as regression coefficient beta or mean difference and 95% confidence intervals. For postexercise values, logistic regression analysis was used and results are reported as odds ratios and 95% confidence intervals. Multivariable model included age, OCS treatment, sensitization, and rhinovirus etiology at study entry. Significant associations are shown bold and italic. B‐eos, blood eosinophil count; 25‐OH‐D, 25‐hydroxyvitamin D; ICS, inhaled corticosteroid; n/a, not applicable; OCS, oral corticosteroid; Rrs, resistance; RSV, respiratory syncytial virus.
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3.4. Bronchial reactivity {#all13593-sec-0017}
-------------------------

Increased bronchial reactivity was diagnosed in 9/75 (12%) children. Eight (11%) of these changes were diagnosed in the exercise test as a Rrs 5 Hz increase of ≥35%, and one (1%) of the children had a Rrs 5 Hz decrease of ≥35% following administration for salbutamol. Increased bronchial reactivity induced by exercise was more common in children who had atopic eczema (OR 14; 95%CI 2.7 to 72; *P *=* *0.002) or atopic sensitization (OR 10; 95%CI 1.8 to 55; *P *=* *0.008) at the time of the first wheezing episode. The association with atopic sensitization (OR 8.8; 95%CI 1.2 to 64; *P *=* *0.032) remained in multivariable analysis which included age at study entry, OCS for the first wheezing episode, atopic sensitization, and rhinovirus etiology at study entry (Table [2](#all13593-tbl-0002){ref-type="table"}). The exercise‐induced change in Rrs 5 Hz was significantly greater in children with atopic sensitization at study entry (β 0.74; 95%CI 0.28 to 1.2; *P *=* *0.002), atopic eczema at study entry (β 0.90; 95%CI 0.35 to 1.4; *P *=* *0.002), hospitalization at study entry (β 0.73; 95%CI 0.18 to 1.3; *P *=* *0.010), or ICS use within 4 weeks (β 0.70; 95%CI 0.080 to 1.3; *P *=* *0.028). In adjusted analysis, which included age at study entry, hospitalization, OCS use at study entry, ICS use within 4 weeks, atopic sensitization at study entry, and rhinovirus etiology, atopic sensitization remained statistically significant (β 0.54; 95%CI 0.027 to 1.1; *P *=* *0.027). The changes in postbronchodilator values were not affected by any of the factors shown in Table [2](#all13593-tbl-0002){ref-type="table"} (Table [S3](#all13593-sup-0001){ref-type="supplementary-material"}). Postexercise or postbronchodilator Rrs 10 values were not affected by any of the factors shown in Table [2](#all13593-tbl-0002){ref-type="table"} (data not shown).

There were no statistically significant differences in bronchial reactivity depending on the age, sex, or virus etiology. However, all 8 children with pathological exercise‐induced bronchial reactivity (≥35%) were rhinovirus positive during the first wheezing episode. Likewise, other patient characteristics shown in Table [1](#all13593-tbl-0001){ref-type="table"} were not associated with bronchial reactivity.

3.5. The effect of corticosteroid treatment {#all13593-sec-0018}
-------------------------------------------

The OCS treatment during the first wheezing episode did not affect the pulmonary function four years later. There were no significant differences in baseline IOS parameters (all *P *≥* *0.13) or in exercise‐induced bronchial reactivity (*P *≥* *0.16) between the prednisolone and placebo groups. In the 12 children who were not able to discontinue the ICS use, the exercise‐induced change in Rrs 5 Hz was greater than that in non‐ICS users (β 0.70; 95%CI 0.080 to 1.3; *P *=* *0.028), but this association did not remain in adjusted analysis (Table [2](#all13593-tbl-0002){ref-type="table"}, Table [S3](#all13593-sup-0001){ref-type="supplementary-material"}). The results without the children using continuous ICS treatment before the follow‐up visit were not markedly different (data not shown).

4. DISCUSSION {#all13593-sec-0019}
=============

To our knowledge, this is the first study to investigate the associations between the patient characteristics of the first acute severe virus‐induced wheezing episode and the subsequent pulmonary function and bronchial reactivity later in childhood. As a main finding, atopic sensitization, both aeroallergen and food sensitization, during the first wheezing episode was associated with increased bronchial reactivity at preschool age. We did not find any significant association between the rhinovirus or its genome load, other virus infections, or other patient characteristics at study entry and the later pulmonary function or bronchial reactivity.

Previous studies have reported that the early atopic sensitization is an important predictor for reduced pulmonary function in later life.[4](#all13593-bib-0004){ref-type="ref"}, [6](#all13593-bib-0006){ref-type="ref"}, [7](#all13593-bib-0007){ref-type="ref"} Illi et al[4](#all13593-bib-0004){ref-type="ref"} first recognized that the pulmonary function was impaired from age 7 to 13 years in children with earlier atopic wheezing but not in children with earlier nonatopic wheezing. Turner et al[6](#all13593-bib-0006){ref-type="ref"} demonstrated that the infant atopy is associated with the reduction of pulmonary function measured by rapid thoraco‐abdominal compression technique or spirometry from the age of 1 month to 18 years. Moreover, Belgrave et al[7](#all13593-bib-0007){ref-type="ref"} found that number of early specific sensitizations correlated inversely with pulmonary function measured by plethysmography from the age of 3 to 11 years. Our finding extends these results by showing that atopic sensitization at the time of the first severe wheezing episode is associated with increased bronchial reactivity measured by IOS in addition to a reduction in pulmonary function in a long‐term follow‐up to the age of 5 years. The link between allergic airway inflammation and subsequent increased bronchial reactivity is incompletely understood. The possible explanations are related to immune dysregulation and promotion of type 2 cytokines, for example IL‐13, and counteracting Th1‐mediated mechanisms, for example interferon expression, which are important in viral defense.[1](#all13593-bib-0001){ref-type="ref"} Allergic airway inflammation may also weaken epithelial barrier function and thereby increase susceptibility to viral infections.[37](#all13593-bib-0037){ref-type="ref"}

Previous studies have shown parental asthma and maternal smoking to be associated with baseline pulmonary function and/or bronchial reactivity.[5](#all13593-bib-0005){ref-type="ref"}, [8](#all13593-bib-0008){ref-type="ref"} Some studies have also found an association between these patient characteristics and decreasing pulmonary function during a follow‐up until the age of 18 years.[6](#all13593-bib-0006){ref-type="ref"}, [7](#all13593-bib-0007){ref-type="ref"} Vitamin D has been found to be potential in preventing infectious diseases and atopic illnesses through both innate and adaptive immune responses.[38](#all13593-bib-0038){ref-type="ref"}, [39](#all13593-bib-0039){ref-type="ref"}, [40](#all13593-bib-0040){ref-type="ref"} In our study, patient characteristic data were carefully assembled and 25‐OH‐D levels were analyzed. However, we did not find associations between any of these patient characteristics and IOS parameters. Association between rhinovirus genome load and pulmonary function has not been investigated earlier. We did not find any association between viral load and IOS parameters as well. In our study, the mean age of the children during the pulmonary function testing was lower when compared to the earlier studies (mean 5 years vs 7.2‐11 years), which may partly explain the negative results. The low sensitivity of IOS is another probable explanation for the negative results. Moreover, this is the first study concentrating on the first acute virus‐induced wheezing episode, and thus, our results underline the role of sensitization as an early risk marker for later bronchial reactivity.

Earlier studies have shown decreased baseline pulmonary function in 20%‐29% of cases 6‐8 years after virus‐induced bronchiolitis.[8](#all13593-bib-0008){ref-type="ref"}, [9](#all13593-bib-0009){ref-type="ref"}, [19](#all13593-bib-0019){ref-type="ref"} In our study, the proportion of pathological pulmonary function at baseline was low (3%). Our detection rate of exercise‐induced bronchial reactivity (11%) is also relatively low when compared to earlier studies (13%‐62%).[8](#all13593-bib-0008){ref-type="ref"}, [9](#all13593-bib-0009){ref-type="ref"}, [19](#all13593-bib-0019){ref-type="ref"} In our study, twelve (32%) of the 37 children were not able to discontinue the ICS medication for asthma, which may partly explain the low detection rate of increased bronchial reactivity. However, in majority (68%) of the children using ICS, the medication was discontinued at least four weeks before the IOS testing. According to the Finnish guidelines,[41](#all13593-bib-0041){ref-type="ref"} which are in line with the US National Asthma Education and Prevention Program guidelines,[35](#all13593-bib-0035){ref-type="ref"} regular long‐term asthma control medication is started relatively early in life. Although unproven, this may lead to better management of asthma already during early childhood and minor pulmonary function impairment at preschool age.

Pulmonary function measurement in young children is technically challenging. IOS is a relatively new method and that has been shown to be promising from the age 2‐3 years onward due to its requirements of minimum cooperation.[20](#all13593-bib-0020){ref-type="ref"}, [21](#all13593-bib-0021){ref-type="ref"}, [24](#all13593-bib-0024){ref-type="ref"} Success rate of IOS in our study was 99%, and exercise testing was conducted successfully in 96% of the children. This supports the role of IOS as a preferred pulmonary function testing method in young children and exercise test as a practicable method for bronchial reactivity testing already in preschool‐aged children. Rrs is dependent on the height of the child and frequency of the signal. We used the Finnish population‐based height‐adjusted reference values,[20](#all13593-bib-0020){ref-type="ref"}, [23](#all13593-bib-0023){ref-type="ref"} which makes the results more reliable.

Strengths of our study include the prospective design, new focus on the first wheezing episode, comprehensive viral diagnostics, the use of IOS for pulmonary function testing, good quality of the IOS measurements, and discontinuation of regular asthma controller medication in majority of asthmatic children before testing. Allergen‐specific IgE was used for characterization of atopic sensitization. The children were carefully examined by a physician, and the standard questionnaire was used which provided detailed characterization of the children.[42](#all13593-bib-0042){ref-type="ref"} However, our study has some limitations. Most patients were hospitalized during the first acute wheezing episode, which makes these results only applicable for the most severe end of illness. The relatively small study population precluded analysis of rhinovirus species or the associations of other respiratory viruses with spirometry outcomes. Reasonable challenge in exercise test was ensured by continuous heart rate monitoring, but ventilation was not measured for this purpose.

In conclusion, atopic sensitization diagnosed during the first acute severe wheezing episode was associated with increased bronchial reactivity and reduced lung function at preschool age. Clinically, these results suggest that testing for atopic sensitization at the time of first wheezing episode may have prognostic significance with respect to lung function. These results are also important to consider for the design of early intervention trials for secondary prevention of asthma.
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